525 related articles for article (PubMed ID: 19931080)
1. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
2. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
Lemay A; Dodin S; Turcot L; Déchêne F; Forest JC
Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
[TBL] [Abstract][Full Text] [Related]
6. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
[TBL] [Abstract][Full Text] [Related]
7. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
[TBL] [Abstract][Full Text] [Related]
8. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Ye BL; Yang HY; Zhao JZ; Lin JJ; Lin WQ
Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
Bhattacharya SM; Jha A
Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
[TBL] [Abstract][Full Text] [Related]
10. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I
Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
[TBL] [Abstract][Full Text] [Related]
11. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.
Cinar N; Harmanci A; Bayraktar M; Yildiz BO
Clin Endocrinol (Oxf); 2013 Mar; 78(3):379-84. PubMed ID: 22509734
[TBL] [Abstract][Full Text] [Related]
12. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.
Gode F; Karagoz C; Posaci C; Saatli B; Uysal D; Secil M; Akdeniz B
Arch Gynecol Obstet; 2011 Oct; 284(4):923-9. PubMed ID: 21140159
[TBL] [Abstract][Full Text] [Related]
13. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
14. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Wang QY; Song Y; Huang W; Xiao L; Wang QS; Feng GM
Chin Med J (Engl); 2016 Apr; 129(8):883-90. PubMed ID: 27064030
[TBL] [Abstract][Full Text] [Related]
16. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
Kaya MG; Calapkorur B; Karaca Z; Yildirim S; Celik A; Akpek M; Unluhizarci K; Kelestimur F
Clin Endocrinol (Oxf); 2012 Dec; 77(6):885-92. PubMed ID: 22563947
[TBL] [Abstract][Full Text] [Related]
17. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
18. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
19. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
Meyer C; McGrath BP; Teede HJ
Diabetes Care; 2007 Mar; 30(3):471-8. PubMed ID: 17327307
[TBL] [Abstract][Full Text] [Related]
20. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
